首页|前列舒通联合盐酸坦索罗辛治疗慢性非细菌性前列腺炎的临床疗效分析

前列舒通联合盐酸坦索罗辛治疗慢性非细菌性前列腺炎的临床疗效分析

扫码查看
目的 分析前列舒通联合盐酸坦索罗辛治疗慢性非细菌性前列腺炎的临床疗效.方法 82 例慢性非细菌性前列腺炎患者,根据随机数字表法分为常态组和科研组,每组 41 例.常态组患者采用前列舒通单一用药方式,科研组患者采用前列舒通联合盐酸坦索罗辛治疗方案.比较两组患者治疗前后美国国立卫生研究院慢性前列腺炎症状指数量表(NIH-CPSI)评分、促炎因子水平[白细胞计数(WBC)、白细胞介素-1β(IL-1β)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)],治疗后排尿指标,临床疗效.结果 治疗后,科研组患者NIH-CPSI的排尿症状、疼痛症状、严重程度、生活质量评分及总分分别为(3.53±0.60)、(6.24±1.12)、(9.77±2.05)、(6.21±1.02)、(15.98±2.66)分,低于常态组的(4.87±0.92)、(9.67±1.21)、(14.54±2.39)、(8.98±1.26)、(23.52±3.82)分,组间比较具有统计学差异(P<0.05).治疗后,科研组患者的尿急次数、最大尿流量、夜尿次数以及排尿次数分别为(2.52±0.21)次/d、(17.18±2.45)ml/s、(1.83±0.28)次/晚、(6.32±1.41)次/d,均低于常态组的(5.09±0.87)次/d、(21.43±3.36)ml/s、(3.31±0.56)次/晚、(10.24±2.17)次/d,组间比较具有统计学差异(P<0.05).治疗后,科研组患者的WBC、IL-1β、IL-8、TNF-α水平分别为(10.35±1.08)个/HP、(54.73±10.04)pg/ml、(5.73±0.98)ng/ml、(42.34±8.01)ng/ml,低于常态组的(12.64±1.73)个/HP、(68.25±10.71)pg/ml、(7.85±1.04)ng/ml、(57.02±8.23)ng/ml,组间比较具有统计学差异(P<0.05).科研组患者的临床总有效率 92.68%高于常态组患者的 73.17%,组间比较具有统计学差异(P<0.05).结论 对于慢性非细菌性前列腺炎患者而言,运用前列舒通联合盐酸坦索罗辛治疗方案能够明显改善其症状、排尿指标,缩短康复时间,具有较好的临床疗效.
Clinical effect analysis of Qianlie Shutong combined with tamsulosin hydrochloride in the treatment of chronic nonbacterial prostatitis
Objective To analyze the clinical effect of Qianlie Shutong combined with tamsulosin hydrochloride in the treatment of chronic nonbacterial prostatitis.Methods A total of 82 patients with chronic nonbacterial prostatitis were divided into a normal group and a research group according to random number table method,with 41 cases in each group.Patients in the normal group were treated with Qianlie Shutong alone,and patients in the research group were treated with Qianlie Shutong combined with tamsulosin hydrochloride.Comparison was made on National Institutes of Health Chronic Prostatitis Symptom Index(NIH-CPSI)score,proinflammatory factors[white blood cell count(WBC),interleukin-1β(IL-1β),interleukin-8(IL-8),tumor necrosis factor-α(TNF-α)]levels,urination indicators after treatment,and clinical effect between the two groups.Results After treatment,the scores of urination symptoms,pain symptoms,severity,quality of life and total score in the research group were(3.53±0.60),(6.24±1.12),(9.77±2.05),(6.21±1.02)and(15.98±2.66)points,which were lower than(4.87±0.92),(9.67±1.21),(14.54±2.39),(8.98±1.26)and(23.52±3.82)points in the normal group,and there was statistical difference between groups(P<0.05).After treatment,the number of urgent urination,the maximum urine flow,the number of nocturnal urination and the number of urination in the research group were(2.52±0.21)times/d,(17.18±2.45)ml/s,(1.83±0.28)times/night and(6.32±1.41)times/d,which were lower than(5.09±0.87)times/d,(21.43±3.36)ml/s,(3.31±0.56)times/night,and(10.24±2.17)times/d in the normal group,and there was statistical difference between groups(P<0.05).After treatment,the levels of WBC,IL-1β,IL-8 and TNF-α in the research group were(10.35±1.08)/HP,(54.73±10.04)pg/ml,(5.73±0.98)ng/ml and(42.34±8.01)ng/ml,which were lower than(12.64±1.73)/HP,(68.25±10.71)pg/ml,(7.85±1.04)ng/ml,(57.02±8.23)ng/ml in the normal group,and there were statistical differences between groups(P<0.05).The total clinical effective rate of 92.68%in the research group was higher than 73.17%in the normal group,and there were statistical differences between groups(P<0.05).Conclusion For patients with chronic nonbacterial prostatitis,the combination of Qianlie Shutong and tamsulosin hydrochloride can significantly improve their symptoms and urination indicators,shorten the recovery time,and have a good clinical effect.

Qianlie ShutongTamsulosin hydrochlorideChronic nonbacterial prostatitisClinical effectAnalysis

巩春武

展开 >

276023 临沂市第三人民医院普外科

前列舒通 盐酸坦索罗辛 慢性非细菌性前列腺炎 临床疗效 分析

2024

中国实用医药
中国康复医学会

中国实用医药

影响因子:0.797
ISSN:1673-7555
年,卷(期):2024.19(3)
  • 12